Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
RegulatoryapprovedCasgevyPositive
AI Analysis
Summary
Vertex Pharmaceuticals received FDA approval for Casgevy for pediatric patients with sickle cell disease or transfusion-dependent β-thalassemia. United Therapeutics announced an acquisition of a startup.
Outcome Details
Casgevy approved for pediatric patients with sickle cell disease or transfusion-dependent β-thalassemia
Importance:9/10
Sentiment:
0.80
FDA approvalGene therapyPediatric indicationSickle cell diseaseBeta-thalassemiaM&A
Read the original article
Published by Endpoints News on July 2, 2026 2:10 PM